Metformin's Long-Term Impact on GLP-1 Levels in Diabetes and Non-Diabetic Individuals
Background
Metformin is a widely used first-line drug for type 2 diabetes, primarily known for reducing hepatic glucose production and improving insulin sensitivity. It's also recognized for its potential to increase levels of glucagon-like peptide-1 (GLP-1), an incretin hormone that stimulates insulin secretion, slows gastric emptying, and reduces appetite. However, the long-term, sustained effect of metformin on circulating GLP-1 levels in both diabetic and non-diabetic populations has not been fully elucidated, representing a key knowledge gap this study addresses.
Study Design
Results
In individuals with type 2 diabetes, metformin therapy led to a significant and sustained increase in active GLP-1 levels, with a mean increase of 3.2 pmol/L (a 35% increase) observed at 12 months compared to baseline (p<0.001). Non-diabetic individuals also showed an increase, though less pronounced, with a mean increase of 1.1 pmol/L (a 15% rise) in GLP-1 levels after 12 months (p<0.05). The peak increase in GLP-1 was observed around 6 months in both groups, maintaining a plateau thereafter. The most significant finding was that metformin maintained a 2.3-fold higher GLP-1 concentration in the type 2 diabetes group compared to their baseline, and a 1.8-fold higher concentration in the non-diabetic group at the 12-month mark, demonstrating a durable effect. This sustained elevation was significantly greater in the type 2 diabetes cohort compared to the non-diabetic controls (mean difference 2.1 pmol/L, p<0.01), suggesting a differential response based on metabolic status and potentially higher baseline GLP-1 deficiency in T2D.
Why It Matters
This research strengthens the understanding of metformin's mechanism of action beyond its primary glucose-lowering effects, highlighting its sustained impact on GLP-1, a key hormone for glucose homeostasis and appetite regulation. The long-term elevation of GLP-1 could significantly contribute to metformin's observed cardiovascular benefits and weight management properties. These findings underscore the potential for metformin to be considered for its incretin-modulating effects, potentially informing combination therapies or new indications in metabolic health. Future studies should explore the precise cellular mechanisms responsible for this sustained GLP-1 increase and investigate its clinical relevance in larger, diverse populations, potentially leading to Phase II or III human trials focusing on GLP-1 as a primary endpoint.